Bronchial asthma - Issues for the developing world

Indian Journal of Medical Research

Volumn 142, Issue April, 2015, Pages 380-382

  Behera, D ^a   Sehgal, Inderpaul Singh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEBRIKIZUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHYLXANTHINE; OMALIZUMAB;

ASTHMA; CLINICAL FEATURE; DISEASE CONTROL; EDITORIAL; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INDIA; LUNG FUNCTION; META ANALYSIS (TOPIC); PREVALENCE; QUALITY OF LIFE; SUBCUTANEOUS IMMUNOTHERAPY; ASPERGILLUS FUMIGATUS; DEVELOPING COUNTRY; MICROBIOLOGY; PATHOGENICITY;

ASPERGILLUS FUMIGATUS; ASTHMA; DEVELOPING COUNTRIES; HUMANS;

EID: 84932168788     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.159237     Document Type: Editorial

References (24)

1. Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India 2015; 32: S3-42.
2. Masoli M, Fabian D, Holt S, Beasley R; global Initiative for Asthma (GINA) programme. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-78.
3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012; 12: 204.
4. The Global Asthma Report 2014. Auckland, New Zealand:Global Asthma Network, 2014. Available from: http://www.globalasthmareport.org/resources/Global_ Asthma_Report_ 2014.pdf, accessed on February 16, 2015.
5. Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, Jindal SK, et al. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Indian J Chest Dis AlliedSci 2006; 48: 13-22.
6. Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One 2014; 9: e114745.
7. Murthy KJR, Sastry JG. Economic burden of asthma. In: Burden of disease in India. Background papers. Available from: http://www.who.int/macrohealth/action/NCMH_Burden of disease_%2829 Sep%202005%29.pdf, accessed on February 21, 2015.
8. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/, accessed on February 16, 2015.
9. Jindal SK. Burden of asthma in India. Ind J Tuberc Lung Dis 2013; 17: 145.
10. Behera D, Jindal SK. Respiratory symptoms in Indian women using domestic cooking fuels. Chest 1991; 100: 385-8.
11. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012; 308: 987-97.
12. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. NEngl JMed 2007; 356: 2040-52.
13. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. NEngl J Med 2005; 352: 1519-28.
14. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database SystRev 2010; (5): CD005535.
15. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-11.
16. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am JRespir Crit Care Med 2001; 164: 1392-7.
17. Adachi M, Aizawa H, Ishihara K, Ohta K, Sano Y, Taniguchi H, et al. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. Respir Med 2008; 102: 1055-64.
18. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
19. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: Cd003559.
20. Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a metaanalysis of randomized placebo-controlled trials. PLoS One 2013; 8: e59872.
21. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-98.
22. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; CD001186.
23. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61: 1162-72.
24. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43: 850-73.